ALX Oncology Holdings, Inc. (ALXO)

Over the past six months, ALXO's stock price has experienced fluctuations. Key events impacting the stock include Q3 2025 earnings with a GAAP net loss of $22.1 million, analyst ratings from Jefferies and Stifel, FDA Fast Track status for evorpacept to treat head and neck cancer, FDA orphan drug status for evorpacept in blood cancer, positive updated data from the ASPEN-06 Phase 2 trial for HER2-positive gastric cancer, promising anti-tumor activity from the Phase 1b/2 trial of evorpacept in combination with zanidatamab in advanced breast cancer, and the company held its Annual Meeting of stockholders on June 12, 2024.

As a clinical-stage biotechnology company, ALX Oncology Holdings, Inc. currently generates revenue primarily through financing activities. Therefore, traditional demand seasonality for its products and services is not applicable at this stage of its business model.

ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company focused on developing therapies that enhance the immune system to combat cancer. The company's primary focus is on therapies that block the CD47 immune checkpoint, with its lead product candidate being evorpacept, which is undergoing various clinical trials for different cancers. ALX Oncology is also exploring evorpacept in combination with other anti-cancer agents and has preclinical programs for ALTA-002 and ALX2004.

ALX Oncology Holdings, Inc. is headquartered in South San Francisco, California, United States. The company conducts its clinical studies primarily in the United States and collaborates internationally to enroll patients across multiple sites.

In the past year, ALX Oncology's brand reputation has been influenced by positive developments related to its clinical programs and regulatory milestones, including positive analyst coverage and FDA designations. Despite these positive developments, the company's stock has underperformed the US Biotechs industry and the broader US market over the past year. Analysts' projections do not foresee profitability for ALXO in the near term, and the company's cash burn rate is accelerating.

ALX Oncology Holdings Inc. has an ownership structure heavily concentrated in institutional investors, which hold approximately 65-66% of shares. Company insiders own a significant stake of approximately 21.00% of the stock. Major institutional shareholders include venBio Partners LLC, Redmile Group, LLC, Millennium Management Llc, Almitas Capital LLC, Vanguard Group Inc, Acadian Asset Management Llc, BlackRock, Inc., Driehaus Capital Management Llc, Two Sigma Advisers, Lp, and Ameriprise Financial Inc.